FDA’s Draft Agenda for the CFS/ME Patient Input Meeting
This article was originally published in RPM Report
Here is a draft agenda made available by FDA ahead of the April 25-26 first-ever PDUFA V patient input workshop on chronic fatigue syndrome/myalgic encephalomyelitis. FDA notes that a final agenda will be made available a week before the meeting.
You may also be interested in...
CMS remains open to the idea of using parallel review (or, less formal parallel advice) for prescription drugs, but the current and future focus of the pilot program is likely to stay on devices and diagnostics.
Genomic screening of tumor types may be the cutting edge in cancer treatment and a central component of the President’s vision for personalized medicine. But how much evidence is necessary to make insurance coverage for testing routine?
Looking Forward At FDA: Hamburg’s Farewell Notes Challenges; Califf’s First Remarks Focus on Pediatrics
FDA Commissioner Margaret Hamburg is leaving the agency on a high note – and taking the opportunity to urge stakeholders to avoid the temptation to push for changes that will “”weaken or undermine” the agency. Meanwhile, FDA's new Deputy Commissioner of Medical Products Robert Califf makes his first formal remarks in that role during a stakeholder meeting on pediatric research.